🚀 VC round data is live in beta, check it out!
Exelixis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Exelixis and similar public comparables like Orion, ImmunityBio, Recordati, Financiere de Tubize and more.
Exelixis Overview
About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Founded
1994
HQ
Employees
4.6K
Website
Sectors
Financials (LTM)
EV
$10B
Exelixis Financials
Exelixis reported last 12-month revenue of $2B and EBITDA of $1B.
In the same LTM period, Exelixis generated $2B in gross profit, $1B in EBITDA, and $796M in net income.
Revenue (LTM)
Exelixis P&L
In the most recent fiscal year, Exelixis reported revenue of $2B and EBITDA of $977M.
Exelixis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $977M | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 42% | XXX | XXX | XXX |
| EBIT Margin | 38% | XXX | 39% | XXX | XXX | XXX |
| Net Profit | $796M | XXX | $783M | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 34% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Exelixis Stock Performance
Exelixis has current market cap of $11B, and enterprise value of $10B.
Market Cap Evolution
Exelixis' stock price is $41.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $11B | 0.0% | XXX | XXX | XXX | $3.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialExelixis Valuation Multiples
Exelixis trades at 4.2x EV/Revenue multiple, and 9.9x EV/EBITDA.
EV / Revenue (LTM)
Exelixis Financial Valuation Multiples
As of March 21, 2026, Exelixis has market cap of $11B and EV of $10B.
Equity research analysts estimate Exelixis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Exelixis has a P/E ratio of 13.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 10.2x | XXX | XXX | XXX |
| EV/EBIT | 11.0x | XXX | 11.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | 4.4x | XXX | XXX | XXX |
| P/E | 13.6x | XXX | 13.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 11.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Exelixis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Exelixis Margins & Growth Rates
Exelixis' revenue in the last 12 month grew by 12%.
Exelixis' revenue per employee in the last FY averaged $0.5M.
Exelixis' rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Exelixis' rule of X is 72% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Exelixis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 54% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 72% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 23% | XXX | 22% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 35% | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Exelixis Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Orion | XXX | XXX | XXX | XXX | XXX | XXX |
| ImmunityBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Recordati | XXX | XXX | XXX | XXX | XXX | XXX |
| Financiere de Tubize | XXX | XXX | XXX | XXX | XXX | XXX |
| Lupin | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Exelixis M&A Activity
Exelixis acquired XXX companies to date.
Last acquisition by Exelixis was on XXXXXXXX, XXXXX. Exelixis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Exelixis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialExelixis Investment Activity
Exelixis invested in XXX companies to date.
Exelixis made its latest investment on XXXXXXXX, XXXXX. Exelixis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Exelixis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Exelixis
| When was Exelixis founded? | Exelixis was founded in 1994. |
| Where is Exelixis headquartered? | Exelixis is headquartered in United States. |
| How many employees does Exelixis have? | As of today, Exelixis has over 4K employees. |
| Who is the CEO of Exelixis? | Exelixis' CEO is Michael M. Morrissey. |
| Is Exelixis publicly listed? | Yes, Exelixis is a public company listed on Nasdaq. |
| What is the stock symbol of Exelixis? | Exelixis trades under EXEL ticker. |
| When did Exelixis go public? | Exelixis went public in 2000. |
| Who are competitors of Exelixis? | Exelixis main competitors are Orion, ImmunityBio, Recordati, Financiere de Tubize. |
| What is the current market cap of Exelixis? | Exelixis' current market cap is $11B. |
| What is the current revenue of Exelixis? | Exelixis' last 12 months revenue is $2B. |
| What is the current revenue growth of Exelixis? | Exelixis revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Exelixis? | Current revenue multiple of Exelixis is 4.2x. |
| Is Exelixis profitable? | Yes, Exelixis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Exelixis? | Exelixis' last 12 months EBITDA is $1B. |
| What is Exelixis' EBITDA margin? | Exelixis' last 12 months EBITDA margin is 42%. |
| What is the current EV/EBITDA multiple of Exelixis? | Current EBITDA multiple of Exelixis is 9.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.